A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer

LESSONS LEARNED. The combination of everolimus and low‐dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all‐grade NIP occurred in four of ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Lolli, Cristian, Gallà, Valentina, Schepisi, Giuseppe, Barone, Domenico, Burgio, Salvatore Luca, Maugeri, Antonio, Vertogen, Bernadette, Amadori, Dino, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507652/
https://www.ncbi.nlm.nih.gov/pubmed/28546463
http://dx.doi.org/10.1634/theoncologist.2017-0154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507652/
https://www.ncbi.nlm.nih.gov/pubmed/28546463
http://dx.doi.org/10.1634/theoncologist.2017-0154

Ejemplares similares